Related Experiment Video
Updated: Jul 6, 2026

Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Psoriatic arthritis: genetic susceptibility and pharmacogenetics
Proton Rahman1, Darren D O'Rielly
1Memorial University, Discipline of Rheumatology, School of Pharmacy and Faculty of Medicine, Health Science Centre, 300 Prince Philip Drive, St John's, NL, A1B 3V6, Canada. prahman@mun.ca
Abstract:
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. The etiology of PsA is unknown; however, there is mounting evidence for a strong genetic contribution to PsA. A few disease-related genes have already been identified in PsA. Cytokines associated with PsA appear to be the most promising targets for pharmacogenetics. Blockade of TNF-alpha and IL-12/23 is associated with a marked clinical response to PsA and/or psoriasis, implying a pivotal role of these cytokines in the pathogenesis of these two disease entities. To date, only the -308 variant of the TNF-alpha promoter gene has been shown to be important in predicting response to TNF-alpha blockade in inflammatory arthritis.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters